Dr. Eric A. Gershman, MD

Dr. Gershman practices at Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida.

Dr. Gershman's NPI, 1316903768, was assigned on April 25, 2006. Dr. Gershman graduated from Universidad Central del Caribe School of Medicine in 1986. Dr. Gershman holds Florida license ME55276.

Dr. Gershman's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West, at 1708 Cape Coral W Pkwy, Cape Coral, FL 33914 in Lee County. The practice phone is (239) 541-4633.

Dr. Gershman's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida. Dr. Gershman is also affiliated with AdventHealth Daytona Beach. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Gershman to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gershman practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Gershman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Gershman is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Gershman's licenses on file in 12 states: Florida, Idaho, Nevada, Oregon, California, New York, Oklahoma, Georgia, Alabama, Wisconsin, Pennsylvania and Louisiana.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphoma and multiple myeloma among the conditions Dr. Gershman treats.

CMS data shows 7,979 Medicare services from Dr. Gershman across 16 procedure codes in 2024, for 198 Medicare patients. Medicare paid $37,474 for them.

CMS counts 198 Medicare patients who saw Dr. Gershman in 2024. The largest group is 75 to 84, with 83 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gershman's median patient age at 73, with 58% women.

In 2024, Dr. Gershman wrote 956 Medicare Part D claims for 209 patients. 65% of them were for generic drugs. CMS names the drug for 738 of them, across 26 drugs with 11 or more claims each, at $3,024,623 in total drug cost. In 2023, CMS named 553 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Gershman for performance year 2024, reported as part of a group. Dr. Gershman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 973 general payments to Dr. Gershman from 72 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 51% of the total. AstraZeneca Pharmaceuticals LP paid the most, $7,203.

Dr. Gershman graduated from Universidad Central del Caribe School of Medicine in 1986. Dr. Gershman is a member of ASCO.

Dr. Gershman is in network with 20 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.